Key Points
- InspireMD director Paul Stuka bought 65,626 shares at an average price of $1.16, increasing his stake by 11.78% to 622,871 shares. The purchase was disclosed in an SEC filing and was made under a pre-arranged Rule 10b5-1 trading plan.
- Stuka also made several earlier purchases in the same week, including 10,000 shares on May 11 and smaller buys on May 7 and May 6. These repeated transactions suggest continued insider accumulation of InspireMD stock.
- Analysts remain generally bullish on the company, with a consensus Buy rating and average price target of $4.50. However, the stock was trading near $1.20, well below analyst targets and close to its 52-week low.
InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Paul Stuka bought 10,000 shares of the company's stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $1.19 per share, for a total transaction of $11,900.00. Following the transaction, the director directly owned 632,871 shares in the company, valued at $753,116.49. This trade represents a 1.61% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Paul Stuka also recently made the following trade(s):
- On Friday, May 8th, Paul Stuka bought 65,626 shares of InspireMD stock. The shares were acquired at an average price of $1.16 per share, for a total transaction of $76,126.16.
- On Thursday, May 7th, Paul Stuka bought 6,378 shares of InspireMD stock. The shares were acquired at an average price of $1.15 per share, for a total transaction of $7,334.70.
- On Wednesday, May 6th, Paul Stuka bought 1,517 shares of InspireMD stock. The shares were acquired at an average price of $1.12 per share, for a total transaction of $1,699.04.
InspireMD Trading Down 4.0%
NYSE NSPR opened at $1.20 on Wednesday. The stock has a market capitalization of $56.21 million, a price-to-earnings ratio of -1.60 and a beta of 0.82. The business's 50 day moving average is $1.47 and its two-hundred day moving average is $1.73. InspireMD, Inc. has a 12-month low of $1.02 and a 12-month high of $2.93.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on NSPR shares. Piper Sandler restated an "overweight" rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on InspireMD in a report on Monday, May 4th. Maxim Group initiated coverage on InspireMD in a research note on Monday, February 2nd. They set a "buy" rating and a $6.00 price target on the stock. Finally, Loop Capital set a $5.00 price target on InspireMD in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $4.50.
Read Our Latest Analysis on InspireMD
Institutional Trading of InspireMD
Several large investors have recently added to or reduced their stakes in NSPR. Aberdeen Group plc acquired a new stake in InspireMD in the 3rd quarter valued at $5,979,000. Rosalind Advisors Inc. grew its stake in shares of InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company's stock valued at $9,413,000 after acquiring an additional 1,616,644 shares in the last quarter. Velan Capital Investment Management LP grew its stake in shares of InspireMD by 137.1% during the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company's stock valued at $5,166,000 after acquiring an additional 1,239,669 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in InspireMD by 97.6% in the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company's stock worth $5,882,000 after purchasing an additional 1,205,328 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its stake in InspireMD by 45.7% in the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company's stock worth $8,137,000 after purchasing an additional 1,058,467 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.
About InspireMD
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
